Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma

(2013) Jayne S. Wilson et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

(2012) S. G. DuBois et al.   CLINICAL CANCER RESEARCH

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

(2011) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis

(2010) Zhe-Yi Hu et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2010) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics

(2008) John F. Deeken et al.   CANCER

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

(2008) Steven G. DuBois et al.   NUCLEAR MEDICINE AND BIOLOGY

Reducing irinotecan-associated diarrhea in children

(2007) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER